Medicaid

GE HealthCare Establishes the GE HealthCare Foundation

Building on GE HealthCare’s legacy in medical technology, the GE HealthCare Foundation will advance equitable access to precision healthcare with…

2 years ago

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

VAN NUYS, Calif.--(BUSINESS WIRE)--The Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System…

2 years ago

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use…

2 years ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc.…

2 years ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

SUNNYVALE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for…

2 years ago

Findhelp and Foothold Partner to Support New York State’s Medicaid 1115 Waiver Program by Integrating Social Care Referral Management to Address Health-Related Social Needs

Nation's largest social care network expands presence in New York and beyond following new integration partnership with Foothold Care Management…

2 years ago

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,…

2 years ago

Avenues Expands Its Services to Colorado

Avenues Recovery Center Opens New 130- Bed Facility in Aurora, ColoradoAURORA, CO / ACCESSWIRE / March 5, 2024 / Avenues…

2 years ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device…

2 years ago

Innsena Appoints Britteny Matero to Partner and Senior Vice President

Matero to lead Innsena’s market access line of business, drive collaborative efforts to improve care outcomes for underserved communities and…

2 years ago